Pegfilgrastim

CLINICAL USE

Pegylated recombinant human granulocyte-colony stimulating factor (rhG-CSF):Reduction of duration of neutropenia (except in chronic myeloid leukaemia and myelodysplastic syndromes)

DOSE IN NORMAL RENAL FUNCTION

6 mg given approximately 24 hours post chemotherapy

PHARMACOKINETICS

Molecular weight :39 000

%Protein binding :Very high (filgrastim)

%Excreted unchanged in urine : Minimal

Volume of distribution (L/kg) :0.15 (filgrastim)

half-life – normal/ESRD (hrs) :15–80/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Not dialysed. Dose as in normal renal function

HD :Not dialysed. Dose as in normal renal function

HDF/high flux :Unlikely to be dialysed. Dose as in normal renal function

CAV/VVHD :Not dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsCytotoxics: neutropenia possibly exacerbated if administered with fluorouracil

ADMINISTRATION

Reconstition

–

Route

Rate of Administration

–

Comments

Incompatible with sodium chloride solutionsDiscard after 72 hours if left at room temperature

OTHER INFORMATION

Pegfilgrastim is a sustained-release form of filgrastim.

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home